RA VII86229-97-2RA-VIIHVM25O0351RA-700(1S,4R,7S,10S,13S,16S)-24-methoxy-10-[(4-methoxyphenyl)methyl]-4,7,9,13,15,29-hexamethyl-22-oxa-3,6,9,12,15,29-hexazatetracyclo[14.12.2.218,21.123,27]tritriaconta-18,20,23,25,27(31),32-hexaene-2,5,8,11,14,30-hexoneCYCLO(D-ALANYL-L-ALANYL-N,O-DIMETHYL-L-TYROSYL-L-ALANYL-N-METHYL-L-TYROSYL-3-HYDROXY-N,O-DIMETHYL-L-TYROSYL), CYCLIC (5->6)-ETHER(1S,4R,7S,10S,13S,16S)-24-methoxy-10-((4-methoxyphenyl)methyl)-4,7,9,13,15,29-hexamethyl-22-oxa-3,6,9,12,15,29-hexazatetracyclo(14.12.2.218,21.123,27)tritriaconta-18,20,23,25,27(31),32-hexaene-2,5,8,11,14,30-hexoneRefChem:930528Methylether of TPC-AUNII-HVM25O03516-(3-Hydroxy-N,O-dimethyl-L-tyrosine)-5-(N-methyl-L-tyrosine)bouvardin
UsesRA-VII is an antitumor agent that exhibits significant activity against L1210, B-16 melanoma, Lewis lung carcinoma, Colon 38 and Ehrlich carcinoma[1].